Back to search

Peptide record

TPDB18385

Antibacterial Anticancer Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB18385
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.
Sequence
CLLRRLLRRLLRR
Physicochemical Analysis
C75H145N31O14S1
ANDEQGHIKMFPSTWYV
RL
1737.24
12.70
6
0
6
+6
1.26
-0.131
180.00
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
6
R
0
N
0
D
1
C
0
E
0
Q
0
G
0
H
0
I
6
L
0
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 6 N: 0 D: 0 C: 1 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 6 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C75H145N31O14S1
1737.24
12.70
+6
1.26
-0.131
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
Toxicity
24±5 µM
Cytotoxic
IC50 | 24±5 | µM | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Rationally designed short cationic α-helical peptides with selective anticancer activity. | J Colloid Interface Sci | 2022
Evidence 2 Activity

Activity

IC50
Toxicity
24
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: HDF: IC50=24±5 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
J Colloid Interface Sci. 2022 Feb 607(Pt 1):488-501.